Elsevier launches PharmaPendium AI, designed to support faster and more reliable access to regulatory insights for drug development

(NYSE:RELX) The solution transforms how insights are gathered from regulatory data, enabling users to quickly identify critical precedents, anticipate approval issues and avoid costly missteps LONDON, Sept. 3, 2025 /PRNewswire/ -- Elsevier, a global information and analytics company, today launches...